Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

pembrolizumab 23Carboplatin 6Pemetrexed 5Paclitaxel 4Cisplatin 4130-nm albumin-bound paclitaxel 3spartalizumab 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Axitinib 2Albumin-Bound Paclitaxel 2trametinib 1ribociclib 1osimertinib 1lenvatinib 1etoposide phosphate 1durvalumab 1dabrafenib 1cemiplimab 1binimetinib 1Vascular Endothelial Growth Factor A 1Nivolumab 1Gemcitabine 1Etoposide 1Doxorubicin 1Docetaxel 1DS-8273a 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Parkinson Disease 4, Autosomal Dominant Lewy Body × durvalumab × Clear all
NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

MedImmune LLC

Phase 1 Completed
68 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡